

2021;28(4):259-266. doi: 10.1080/13506129.2021.1971192.

134. Milani P, Basset M, Curci P, et al. Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function. *Blood Adv.* 2020;4(7):1321-1324. doi: 10.1182/bloodadvances.2020001553.

135. Molina-Andújar A, Tovar N, Cuadrado E, et al. Kidney Transplantation in Monoclonal Immunoglobulin Deposition Disease: A Report of 6 Cases. *Am J Kidney Dis.* 2021;78(5):755-759. doi: 10.1053/j.ajkd.2021.02.337.

136. Tushima T, Suzuki T, Terao T, et al. Light chain deposition disease involving kidney and liver in a patient with IgD myeloma. *BMC Nephrol.* 2021;22(1):40. doi: 10.1186/s12882-021-02246-9.

137. Wiklik-Dziadek M, Jaworek-Troć J, Jurczyszyn A. Amyloidosis, extramedullary plasmacytoma, and light chain deposition disease: impressive results of daratumumab therapy. *Pol Arch Intern Med.* 2021;131(3):297-298. doi:10.20452/pamw.15806.

138. Almaani S, Parikh SV, Satoskar AA, et al. Daratumumab in Patients With Bortezomib-Refractory Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits. *Kidney Int Rep.* 2021;6(8):2203-2206. doi: 10.1016/j.ekir.2021.05.008.

139. Coltoff A, Bomback A, Shirazian S, et al. Treatment of Monoclonal Gammopathy-associated C3 Glomerulopathy With Daratumumab-based Therapy. *Clin Lymphoma Myeloma Leuk.* 21(8):e674-e677. doi: 10.1016/j.clml.2021.04.011.

140. Torrealba J, Gattineni J, Hendricks AR. Proliferative Glomerulonephritis with Monoclonal Immunoglobulin G Lambda Deposits: Report of the First Pediatric Case. *Case Rep Nephrol Dial.* 2018;8(1):70-75. doi: 10.1159/000488641.

141. Zand L, Rajkumar SV, Leung N, et al. Safety and Efficacy of Daratumumab in Patients with Proliferative GN with Monoclonal Immunoglobulin Deposits. *J Am Soc Nephrol.* 2021;32(5):1163-1173. doi: 10.1681/ASN.2020101541.

142. Contejean A, Larrousse F, Bouscary D, et al. A clonal mass revealing a disseminated crystal storing histiocytosis secondary to indolent multiple myeloma: a case report with literature review. *BMC Gastroenterol.* 2020;20(1):239. doi: 10.1186/s12876-020-01364-2.

143. Leung N, Bridoux F, Batuman V, et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. *Nat Rev Nephrol.* 2019;15(1):45-59. doi: 10.1038/s41581-018-0077-4.

144. Kastritis E, Theodorakakou F, Roussou M, et al. Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance. *Br J Haematol.* 2021;193(1):113-118. doi: 10.1111/bjh.17052.

145. Koike H, Katsuno M. Paraproteinemia and neuropathy. *Neurol Sci.* 2021;42(11):4489-4501. doi: 10.1007/s10072-021-05583-7.

146. Tiew HW, Sampath VS, Gallardo CA, et al. Single-agent daratumumab for refractory POEMS syndrome. *Am J Hematol.* 2022;97(6):E189-E191. doi: 10.1002/ajh.26517.

147. Leung B, Nelson T, Willenberg R, et al. Failure of Daratumumab Therapy for Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Protein, Skin Changes Syndrome. *J Clin Neuromuscul Dis.* 2021;23(1):56-58. doi: 10.1097/CND.0000000000000370.

148. Gavriatopoulou M, Ntanas-Stathopoulos I, et al. Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome. *Hemasphere.* 2020;4(3):e381. doi: 10.1097/H59.0000000000000381.

149. Khan M, Stone K, van Rhee F. Daratumumab for POEMS Syndrome. *Mayo Clin Proc.* 2018;93(4):542-544. doi: 10.1016/j.mayocp.2018.02.001.

150. Sevindik OG, Mutlu YG, Aydin BB, Serin I. First-line Usage of Daratumumab, Lenalidomide, Dexamethasone (DRd) Combination in a Case of Castleman Disease Variant of Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome (CD-POEMS). *Hemasphere.* 2022;6(7):e728. doi: 10.1097/H59.0000000000000728.

151. Mathew Thomas V, Gilreath JA, et al. Daratumumab as

a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy. *Haemophilia.* 2021;27(4):e563-e566. doi: 10.1111/hae.14323.

152. Nicol C, Raj L, Guillerm G, et al. Acquired von Willebrand syndrome and lymphoproliferative disorders: A case report. *Clin Case Rep.* 2020;8(5):900-904. doi: 10.1002/ccr3.2770.

153. Jeryczynski G, Agis H, Eichinger-Hasenauer S, et al. Successful treatment of acquired von Willebrand syndrome associated with monoclonal gammopathy: Breaking a dangerous bond. *Wien Klin Wochenschr.* 2022;134(11-12):478-482. doi: 10.1007/s00508-022-02012-3.

154. Pinchover LB, Alsharif R, Bernal T. Acquired haemophilia a secondary to multiple myeloma: management of a patient with a mechanical mitral valve. *BMJ Case Rep.* 2020;13(9):e230798. doi: 10.1136/bcr-2019-230798.

155. Krečak I, Ruščić I, Zlatović JJ, et al. Paraneoplastic aortitis in a patient with relapsed multiple myeloma successfully treated with daratumumab, bortezomib and dexamethasone. *Ann Hematol.* 2021;100(6):1623-1624. doi: 10.1007/s00277-020-04369-9.

156. Jian Xu, Wenqi Liu, Fengjuan Fan, et al. TEMPI Syndrome: Update on Clinical Features, Management, and Pathogenesis. *Front Endocrinol (Lausanne)* 2022;13:886961. doi: 10.3389/fendo.2022.886961

157. Zhang X, Fang M. TEMPI Syndrome: Erythrocytosis in Plasma Cell Dyscrasia. *Clin Lymphoma Myeloma Leuk.* 2018;18(11):724-730. doi: 10.1016/j.clml.2018.07.284.

158. Sykes DB, Schroyens W. Complete Responses in the TEMPI Syndrome after Treatment with Daratumumab. *N Engl J Med.* 2018;378(23):2240-2242. doi: 10.1056/NEJMc1804415.

159. Lor M, Cheng M, Liang B, et al. Cheng CE. TEMPI Syndrome With Progressive Telangiectasias Associated With Pulmonary Deterioration. *JAMA Dermatol.* 2020;156(12):1379-1380. doi: 10.1001/jamadermatol.2020.2668.

160. Frerichs KA, Verkleij CPM, Bosman PWC, et al. CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients. *J Transl Autoimmun.* 2019;2:100022. doi:10.1016/j.jtauto.2019.100022.

161. Rieger MJ, Stolz SM, Ludwig S, et al. Daratumumab in rituximab-refractory autoimmune hemolytic anaemia. *Br J Haematol.* 2021;194(5):931-934. doi: 10.1111/bjh.17655.

162. Ofra Y. Daratumumab: new indications revolving around "off-targets". *Haematologica.* 2021;106(12):3032-3033. doi: 10.3324/haematol.2021.279487.

163. Jain A, Gupta DK. Daratumumab for refractory warm autoimmune hemolytic anemia. *Ann Hematol.* 2021;100(5):1351-1353. doi: 10.1007/s00277-020-04063-w.

164. Khandelwal P, Teusink-Cross A, et al. Daratumumab for the management of autoimmune cytopenias in children and young adults: a case series. *Br J Haematol.* 2021;194(5):e84-e89. doi: 10.1111/bjh.17565.

165. Cooling L, Hagan S. Daratumumab in combination with standard treatment for autoimmune hemolytic anemia in a pediatric patient. *Transfusion.* 2019;59(12):3801-3802. doi: 10.1111/trf.15539.

166. Migdady Y, Edirwickrema A, Jackson RP, et al. Successful treatment of thrombocytopenia with daratumumab after allogeneic transplant: a case report and literature review. *Blood Adv.* 2020;4(5):815-818. doi: 10.1182/bloodadvances.2019001215.

167. van den Berg J, Kremer Hovinga JA, Pflieger C, et al. Daratumumab for immune thrombotic thrombocytopenic purpura. *Blood Adv.* 2022;6(3):993-997. doi: 10.1182/bloodadvances.2021005124.

168. Gangat N, Bleeker J, Lynch D, et al. Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia. *Haematologica.* 2022 Jun 9. doi: 10.3324/haematol.2022.281398.

169. Zaninoni A, Giannotta JA, Galli A, et al. The Immunomodulatory Effect and Clinical Efficacy of Daratumumab in a Patient With Cold Agglutinin Disease. *Front Immunol.* 2021;12:649441. doi: 10.3389/fimmu.2021.649441.

170. Tomkins O, Berentsen S, Arulogun S, et al. Daratumum-

ab for disabling cold agglutinin disease refractory to B-cell directed therapy. *Am J Hematol.* 2020; Jul 11. doi: 10.1002/ajh.25932.

171. Asawapanumas T, Chanswangphuwana C, Watanaboonongcharoen P, et al. Daratumumab as a Frontline Immunosuppression for Pure Red Cell Aplasia after Major ABO-mismatched Allogeneic Hematopoietic Stem Cell Transplantation. *Leuk Res Rep.* 2022;17:100314. doi: 10.1016/j.lrr.2022.100314.

172. Bathini S, Holtzman NG, Koka R, et al. Refractory post-allogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab. *Am J Hematol.* 2019;94(8):E216-E219. doi: 10.1002/ajh.25515.

173. Gangat N, Bleeker J, Lynch D, et al. Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia. *Haematologica.* 2022. doi: 10.3324/haematol.2022.281398.

174. Henig I, Yehudai-Ofir D, Zohar Y, et al. Pure Red Cell Aplasia following ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation: Resolution with Daratumumab Treatment. *Acta Haematol.* 2021;144(6):683-687. doi: 10.1159/000515257.

175. Jeyaraman P, Borah P, Rajput P, et al. Daratumumab for pure red cell aplasia post ABO incompatible allogeneic hematopoietic stem cell transplant for aplastic anemia. *Blood Cells Mol Dis.* 2021;88:102464. doi: 10.1016/j.bcmd.2020.102464.

176. Martino R, García-Cadenas I, Esquirol A. Daratumumab may be the most effective treatment for post-engraftment pure red cell aplasia due to persistent anti-donor isohemagglutinins after major ABO-mismatched allogeneic transplantation. *Bone Marrow Transplant.* 2022;57(2):282-285. doi: 10.1038/s41409-021-01507.

177. Rautenberg C, Kaivers J, Gerding U, et al. Daratumumab for treatment of pure red cell aplasia after allogeneic stem cell transplantation. *Bone Marrow Transplant.* 2020;55(6):1191-1193. doi: 10.1038/s41409-019-0664-4.

178. Salas MQ, Alahmari A, Lipton JH. Successful treatment of refractory red cell aplasia after allogeneic hematopoietic cell transplantation with daratumumab. *Eur J Haematol.* 2020;104(2):145-147. doi: 10.1111/iejh.13343.

179. Schuetz C, Hoenig M, Moshous D, et al. Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation. *Blood Adv.* 2018;2(19):2550-2553. doi: 10.1182/bloodadvances.2018020883.

180. Cole S, Walsh A, Yin X, et al. Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus. *Arthritis Res Ther.* 2018;20(1):85. doi: 10.1186/s13075-018-1578-z.

181. Ostendorf L, Burns M, Durek P, et al. Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus. *N Engl J Med.* 2020;383(12):1149-1155. doi: 10.1056/NEJMoa2023325. PMID: 32937047.

182. Bag-Ozbek A, Hui-Yuen JS. Emerging B-Cell Therapies in Systemic Lupus Erythematosus. *Ther Clin Risk Manag.* 2021;17:39-54. doi:10.2147/TCRM.S252592.

183. Humbel M, Bellanger F, Fluder N, et al. Restoration of NK Cell Cytotoxic Function With Elopuzumab and Daratumumab Promotes Elimination of Circulating Plasma Cells in Patients With SLE. *Front Immunol.* 2021;12:645478. doi: 10.3389/fimmu.2021.645478.

184. Scheibe F, Ostendorf L, Prüss H, et al. Daratumumab for treatment-refractory antibody-mediated diseases in neurology. *Eur J Neurol.* 2022;29(6):1847-1854. doi: 10.1111/ene.15266.

185. Scheibe F, Ostendorf L, Reincke SM, et al. Daratumumab treatment for therapy-refractory anti-CASPR2 encephalitis. *J Neurol.* 2020;267(2):317-323. doi: 10.1007/s00415-019-09585-6.

186. Smets I, Titulaer MJ. Antibody Therapies in Autoimmune Encephalitis. *Neurotherapeutics.* 2022;1-9. doi: 10.1007/s13311-021-01178-4.

187. Ratuszny D, Skripuletz T, Wegner F, et al. Daratumumab in a Patient With Severe Refractory Anti-NMDA Receptor Encephalitis. *Front Neurol.* 2020;11:602102. doi: 10.3389/fneur.2020.602102.

188. Dossier C, Prim B, Moreau C, et al. A global antiB cell